JACOBS LEVY EQUITY MANAGEMENT, INC - AMPHASTAR PHARMACEUTICALS IN ownership

AMPHASTAR PHARMACEUTICALS IN's ticker is AMPH and the CUSIP is 03209R103. A total of 134 filers reported holding AMPHASTAR PHARMACEUTICALS IN in Q3 2019. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
JACOBS LEVY EQUITY MANAGEMENT, INC ownership history of AMPHASTAR PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$25,517,552
+15.9%
554,850
+44.8%
0.15%
+18.9%
Q2 2023$22,022,964
+364.7%
383,208
+203.2%
0.13%
+337.9%
Q1 2023$4,739,288
-11.3%
126,381
-33.7%
0.03%
-19.4%
Q4 2022$5,342,630
+1.1%
190,672
+1.4%
0.04%
-14.3%
Q3 2022$5,284,000
-18.8%
188,039
+0.5%
0.04%
-16.0%
Q2 2022$6,510,000
+61.2%
187,129
+66.3%
0.05%
+85.2%
Q1 2022$4,039,000
-7.4%
112,516
-39.9%
0.03%
-6.9%
Q4 2021$4,363,000
+14.1%
187,329
-6.9%
0.03%
+11.5%
Q3 2021$3,823,000
-0.2%
201,128
+5.8%
0.03%0.0%
Q2 2021$3,832,000
+68.4%
190,077
+53.0%
0.03%
+44.4%
Q1 2021$2,276,000
-15.6%
124,230
-7.4%
0.02%
-25.0%
Q4 2020$2,697,000
-11.7%
134,116
-17.7%
0.02%
-25.0%
Q3 2020$3,055,000
-21.6%
162,927
-6.1%
0.03%
-23.8%
Q2 2020$3,898,000
+53.3%
173,572
+1.3%
0.04%
+27.3%
Q1 2020$2,542,000
-26.6%
171,266
-4.6%
0.03%
-2.9%
Q4 2019$3,465,000
-1.5%
179,605
+1.3%
0.03%
-20.9%
Q3 2019$3,516,000
+144.5%
177,321
+160.3%
0.04%
+115.0%
Q2 2019$1,438,000
-3.5%
68,132
-6.6%
0.02%
-9.1%
Q1 2019$1,490,000
+111.9%
72,953
+106.5%
0.02%
+83.3%
Q4 2018$703,000
+3.4%
35,3250.0%0.01%
+20.0%
Q3 2018$680,00035,3250.01%
Other shareholders
AMPHASTAR PHARMACEUTICALS IN shareholders Q3 2019
NameSharesValueWeighting ↓
Alambic Investment Management, L.P. 29,423$583,0000.44%
Matarin Capital Management, LLC 223,184$4,426,0000.34%
Summit Global Investments 42,725$847,0000.10%
FEDERATED HERMES, INC. 1,747,921$34,661,0000.08%
ROTHSCHILD & CO ASSET MANAGEMENT US INC. 347,307$6,887,0000.08%
MARSHALL WACE, LLP 413,293$8,196,0000.06%
BOSTON ADVISORS LLC 42,365$840,0000.04%
MARTINGALE ASSET MANAGEMENT L P 214,444$4,254,0000.04%
JACOBS LEVY EQUITY MANAGEMENT, INC 177,321$3,516,0000.04%
SILVERCREST ASSET MANAGEMENT GROUP LLC 231,041$4,582,0000.04%
View complete list of AMPHASTAR PHARMACEUTICALS IN shareholders